JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target
JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.
A big investment bank's expert said MBX Biosciences looks like a good company to watch again and thinks its stock price could go up. When analysts change their minds in a positive way, it shows they've learned something new that makes them feel better about the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.